Price Arbitration In Medicare: MedPAC Supportive But Congress Running Out Of Time
In its June report to Congress, the Medicare Payment Advisory Commission expands upon previous recommendations for establishing a binding arbitration process to control drug prices in Medicare.
You may also be interested in...
As Washington Waits On Pricing Proposals, A Call For A Reset In R&D Debate
Policymakers should clarify link between high drug prices and innovation and figure out how to “rebalance” high prices with non-price innovation incentives before proceeding with policies aimed directly at lowering prices, Conti and David propose in the Health Affairs Blog.
US Drug Pricing Reforms: ASCO Hears About Bargaining Chips And Baby Steps
Former long-time congressional health staffer Rodney Whitlock discusses the status of prescription drug pricing reform policies in the administration and congress at the American Society for Clinical Oncology annual meeting.
Part B Reforms: MedPAC Moving Forward With 'Drug Value Program' Proposal
Even under most ambitious timeline, new competitive-bidding approach would not start before 2022 – and that assumes Congress has appetite for the legislation with an already full plate of health care work to do. But new ideas in Part B are worth watching.